A pioneering startup combining neuroscience and artificial intelligence, The Biological Computing Company (TBC), is introducing AI models developed from living rat brain cells to select Amazon Web Services customers, marking a significant leap in biological computing applied to video generation.
- TBC uses live rat neurons to improve AI video models on AWS
- The startup raised over $50 million since its 2022 founding
- Biological computing merges living cells with AI for enhanced efficiency
What happened
Starting in September 2026, Amazon Web Services launched a limited preview giving select customers access to The Biological Computing Company’s AI models developed using living rat brain cells. These models are designed to improve AI systems focused on video generation by mimicking the biological processing of visual information.
The Biological Computing Company, founded by neuroscientists and neurosurgeons, cultivates rat brain cells on multi-electrode silicon arrays. These neurons process visual data which TBC analyzes and translates into AI software enhancements. Following initial testing with select AWS clients, the technology is expected to be available to all AWS enterprise customers soon.
Why it matters
Biological computing represents an emerging frontier in AI development, where insights from actual neural networks offer an alternative to purely mathematical algorithm models. By combining living neural tissue with AI software, TBC aims to improve the efficiency and quality of generative video AI, a sector with growing commercial demand.
This approach addresses limitations in current transformer-based AI models and offers a pragmatic pathway to enhance visual data processing. The partnership with AWS also signals increased industry confidence and investment in biologically derived AI technologies, which have historically faced complexity in maintaining live cells and integrating biology with digital computation.
What to watch next
Key developments to monitor include the broader rollout of TBC’s models across AWS’s enterprise client base and performance benchmarks comparing this biological approach to conventional video AI architectures. The company’s continued R&D efforts, including handling human stem cells, may expand the scope beyond video generation into other AI use cases.
Additionally, industry-wide adoption of biological computing will depend on overcoming practical challenges such as cell longevity, scalability, and cost-effectiveness. Funding rounds and collaborations with other bio-AI firms like Cortical Labs may further accelerate progress and commercialization of biohybrid AI systems.